Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $75.0 million
January 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : RNA targeted small molecule
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : $190.0 million
Deal Type : Licensing Agreement
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche
Details : Arrakis will lead discovery and research activities for each target to a defined point, at which time Roche will have the right to exclusively pursue further preclinical and clinical development.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $190.0 million
April 08, 2020
Lead Product(s) : RNA targeted small molecule
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : F. Hoffmann-La Roche
Deal Size : $190.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
